Schematic cross-section of an eye showing potential targets for gene and cell glaucoma therapies: (1) Increased aqueous humor outflow, (2) decreased aqueous humor production, (3) preventing gonioimplant bleb fibrosis, (4) RGC neuroprotection and neuroregeneration, (5) modification of biomechanical properties of sclera, lamina cribrosa, and cornea, and (6) inhibition of inflammation and PIFVM formation.